{{Rsnum
|rsid=529359
|Chromosome=11
|Orientation=minus
|geno1=(A;A)
|geno2=(A;G)
|geno3=(G;G)
|Gene=PGR
|position=101123115
|Gene_s=PGR
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
}}{{ population diversity
| geno1=(A;A)
| geno2=(A;G)
| geno3=(G;G)
| CEU | 39.1 | 53.1 | 7.8
| HCB | 6.7 | 37.8 | 55.6
| JPT | 8.9 | 26.7 | 64.4
| YRI | 12.7 | 57.1 | 30.2
| ASW | 0.0 | 0.0 | 0.0
| CHB | 6.7 | 37.8 | 55.6
| CHD | 0.0 | 0.0 | 0.0
| GIH | 0.0 | 0.0 | 0.0
| LWK | 0.0 | 0.0 | 0.0
| MEX | 0.0 | 0.0 | 0.0
| MKK | 0.0 | 0.0 | 0.0
| TSI | 0.0 | 0.0 | 0.0
| HapMapRevision=28
}}Part of a haplotype [[Gs286]], standalone effect for [[endometrial cancer]] is ambiguous.

In {{PMID|20148360|OA=1
}}, no evidence for linkage to [[colorectal cancer]] in women was found in a study with 158 European subjects and 563 controls.

{{PMID Auto GWAS
|PMID=20547493
|Trait=Endometrial cancer
|Title=Genetic variation in the progesterone receptor gene and risk of endometrial cancer: a haplotype-based approach.
|RiskAllele=C
|Pval=0.031
|OR=1.03
|ORtxt=[0.89-1.2]
|OA=1
}}

{{PMID|20148360|OA=1
}} Genetic variation in sex-steroid receptors and synthesizing enzymes and colorectal cancer risk in women.

{{PMID|12560875}} Catalog of 668 SNPs detected among 31 genes encoding potential drug targets on the cell surface

[[http://oai.dtic.mil/oai/oai?verb=getRecord&metadataPrefix=html&identifier=ADA501717|An Epidemiologic Study of Genetic Variation in Hormonal Pathways in Relation to the Effect of Hormone Replacement Therapy on Breast Cancer Risk]]

{{on chip | 23andMe v1}}
{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}